Novartis presents new migraine data for Aimovig®▼ (erenumab)

People standing in front of a graph to indicate Lost time: Productivity and the flu

Novartis presents new migraine data for Aimovig®▼ (erenumab) demonstrating sustained efficacy to 52 weeks.

Novartis has announced that new data from two follow-up studies of Aimovig® (erenumab) will be presented at the 71st Annual Meeting of the American Academy of Neurology (AAN) in Philadelphia.

Aimovig is specifically designed to prevent migraine by blocking the CGRP receptor, which is involved in the physiological processes associated with migraine. These new data show the potential for Aimovig to reduce the burden of disease for people living with migraine, while also demonstrating sustained benefits over time.

Chronic migraine is defined as 15 or more headache days per month of which eight or more involve migraine symptoms, while episodic migraine is defined as less than 15 headache days per month. A one-year open-label extension (OLE) study looked at the percentage of people with chronic migraine who converted to episodic migraine following treatment with Aimovig. More than two-thirds (72%) of chronic migraine patients converted to episodic migraine, with numerically higher conversion rates at the 140 mg versus 70 mg dosing (76% and 69%, respectively). The conversion is clinically meaningful as evidenced by greater reductions from parent study baseline to week 52 in mean monthly migraine days (MMD) (-12.5 and -10.6 for 140 mg and 70 mg, respectively vs 18.1 at baseline) and higher ≥50% response rates for converters (82% and 71% for 140 mg and 70 mg, respectively).

In a one-year extension of the Phase 3 STRIVE study, data show Aimovig provided sustained efficacy in the prevention of episodic migraine, with 65% (140 mg) and 61% (70 mg) of patients experiencing a 50% or more reduction in MMD. The safety profile was comparable to that observed in prior studies with no new relevant safety findings.

“Aimovig has previously been shown to reduce the number of migraine days in patients with chronic migraine. This follow up data is important as it shows a sustained response at 12 months,” said Dr Alex Sinclair, Consultant Neurologist at University Hospitals Birmingham NHS Foundation Trust (UHB). “Importantly, the safety data is very reassuring over this prolonged time period. Migraine is a highly debilitating and often neglected disease. Targeted migraine therapies are now emerging, marking a step changing advance for the care of migraine patients.”